Vivos Therapeutics released FY2024 annual earnings on March 31 After-Market (EST), actual revenue USD 15.03 M (forecast USD 15.2 M), actual EPS USD -2.2183 (forecast USD -2.02)

Brief Summary

Vivos Therapeutics reported a fiscal year 2024 revenue of USD 15.03 million, which was slightly below the expected USD 15.2 million, along with an EPS of -2.2183 USD, missing the expected -2.02 USD.

Impact of The News

Vivos Therapeutics Financial Briefing Analysis

Performance Overview:

1. Revenue: The company reported actual revenue of USD 15.03 million, which is marginally below the market expectation of USD 15.2 million. This indicates that the company fell short of its revenue targets, reflecting potential challenges in its sales or broader market conditions.
2. Earnings Per Share (EPS): The EPS was reported at -2.2183 USD against an anticipated -2.02 USD. The negative EPS, worse than expected, suggests significant financial difficulties.

Market Comparison:

• Compared to peers such as Guizhou Moutai and Wuliangye, which are expected to maintain double-digit growth in 2024 , Vivos Therapeutics seems to be underperforming. Other companies like Huawei have reported positive revenue growth of 9.6% year-on-year , highlighting Vivos’s relatively weak position.

Transmission Mechanisms and Business Implications:

• Investor Confidence: Missing both revenue and EPS expectations might lead to decreased investor confidence, resulting in potential stock price declines.
• Operational Challenges: The negative financial indicators suggest operational inefficiencies or market challenges, urging the need for strategic reassessment.
• Future Growth Trajectory: Given the current financial situation, Vivos Therapeutics may need to focus on cost management, improving operational efficiency, and possibly exploring new market opportunities to reverse its financial trajectory.